Prevention of cataracts by statins: A meta-analysis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 2, 2014, Pages 191-200

  Kostis, John B ^a   Dobrzynski, Jeanne M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

antioxidants; cataract; meta analysis; pleiotropic effects; statins

Indexed keywords

ANTIOXIDANTS; CATARACT; META-ANALYSIS; PLEIOTROPIC EFFECTS; STATINS;

ANIMALS; CATARACT; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84894464591     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413511690     Document Type: Article

References (38)

1. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 ; 380 (9841). 581-590
2. LaRosa JC, Grundy SM, Waters DD, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352 (14). 1425-1435
3. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012 ; 59 (6). 572-582
4. Khan AR, Riaz M, Bin Abdulhak AA, et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2013 ; 8 (1). e52929
5. Ma Y, Culver A, Rossouw J, et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk?. Ther Adv Cardiovasc Dis. 2013 ; 7A (1). 41-44
6. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's Esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013 ; 11 (6). 620-629
7. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990 ; 50 (1). 65-78
8. JunodSW: Statins: A success story involving FDA, academia and industry. http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/ SelectionsFromFDLIUpdateSeriesonFDAHistory/ucm082054.htm. Accessed February 5, 2013.
9. nd ed. Oradell, NJ: Medical Economics Company Inc; 1988:1365-1367 Oradell, NJ: Medical Economics Company Inc ; 1988: 1365-1367.
10. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci. 2012 ; 89 (8). 1165-1171
11. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc. www.factsardcomparisons.comPublished March 2005. Accessed May 20, 2013.
12. Michael R, Bron AJ. The ageing lens and cataract: a model of normal and pathological ageing. Phil Trans R Soc B. 2011 ; 366 (1568). 1278-1292
13. Varma SD, Kovtun S, Hegde KR. Role of UV irradiation and oxidative stress in cataract formation. medical prevention by nutritional antioxidants and metabolic agonists. Eye Contact Lens. 2011 ; 37 (5). 233-245
14. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxyl-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease. Cardiol Rev. 2010 ; 18 (6). 298-304
15. Norris DM, Anderson JR. Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiol Rev. 2012 ; l20 (6). 319-324
16. Chodick G, Heymann AD, Flash S, Kokia E, Shalev V. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol. 2010 ; 20 (2). 136-142
17. Chylack LT, Mantell G, Wolfe JK, Friends J, Rosner B. Lovastatin and the human lens; results of a two year study. Optom Vis Sci. 1993 ; 70 (11). 937-943
18. Collins GS, Altman DG. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart. 2012 ; 98 (14). 1091-1097
19. Harris ML, Bron AJ, Brown NA, et al. for the Oxford Cholesterol Study Group. Absence of effect of simvastatin on the progression of lens opacities in a randomized placebo controlled study. Br J Ophthalmol. 1995 ; 79 (11). 996-1002
20. Hermans MP, Ahn SA, Rousseau MF. Statin therapy and cataract in type 2 diabetes. Diabetes Metab. 2011 ; 37 (2). 139-143
21. Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA. 2006 ; 295 (23). 2752-2758
22. Laties AM, Shear CL, Lippa EA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results II. assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol. 1991 ; 67 (6). 447-453
23. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study. Arch Intern Med. 1996 ; 156 (18). 2085-2092
24. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med. 2001 ; 161 (16). 2021-2026
25. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM. 2003 ; 96 (5). 337-343
26. Tan JSL, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-term risk of incident cataract: the blue mountains eye study. Am J Ophthalmol. 2007 ; 143 (4). 687-689
27. Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med. 1987 ; 107 (5). 609-615
28. Lundh BL, Nilsson SEG. Lens changes in matched normal and hyperlipidemic patients treated with simvastatin for 2 years. Acta Ophthalmologica. 1990 ; 68 (6). 658-660
29. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000 ; 101 (2). 207-213
30. Kyeong HY, Park H-Y, Choi J-H, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: Rosuvastatin 10 mg versus atorvastatin 20 mg. Korean Circ J. 2007 ; 37 (4). 154-160
31. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing and efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther. 1996 ; (1). 23-30
32. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000 ; 56 (2). 455-463
33. Rosenthal R. The "File drawer problem" and tolerance for null results. Psychol Bull. 1979 ; 86 (3). 638-641
34. Orwin RG. A fail-safe N for effect size in meta-analysis. J Educ Stat. 1983 ; 8 (2). 157-159
35. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta- analysis of randomised statin trials. Lancet. 2010 ; 375 (9716). 735-742
36. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005 ; 46 (8). 1425-1433
37. Varma SD, Kovtun S, Hegde KR. Role of ultraviolet irradiation and oxidative stress in cataract formation-medical prevention of nutritional antioxidants and metabolic agonists. Eye Contact Lens. 2011 ; 37 (4). 233-245
38. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000 ; 342 (25). 1887-1892